293 results about "Isoindoline" patented technology

Solid forms comprising (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions comprising the solid forms, methods of making the solid forms and methods of their use are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4.

Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines reduce the levels of TNFα in a mammal. Typical embodiments are 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4,5,6,7-tetrafuoroisoindoline and 1,3-dioxo-2-(2,6-dioxo-3 -methylpiperidin-3-yl)-4-aminoisoindoline.

Methods of treating cutaneous lupus in a human are disclosed. Specific methods encompass the administration of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione (ACTIMID™), 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (REVLIMID®), or cyclopropyl 2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindolin-4-yl}carboxamide, alone or alternatively, in combination with a second active agent.

This invention relates to N-methylaminomethyl-isoindoline compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

The present application describes 2-(2′,6′-dioxo-3′-deutero-piperidin-3′-yl)isoindoles, deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.

This invention relates to 5-substituted isoindoline compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

Substituted 2-(2,6-dioxopiperidin-3-yl) phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl) isoindolines reduce the levels of TNFα in a mammal. Typical embodiments are 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4,5,6,7-tetrafluoroisoindoline and 1,3-dioxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4-aminoisoindoline.

Novel isoindoline compounds are disclosed. Methods of treating, preventing and/or managing cancer, diseases and disorders associated with, or characterized by, undesired angiogenesis, and diseases and disorders mediated by PDE 4, using the compounds are also disclosed.

Provided herein are isoindoline compounds, pharmaceutical compositions comprising one or more of such compounds, and methods of their use for treating, preventing, or managing various diseases.

The invention relates to a method for production of an aqueous dispersion of polymer-encapsulated pigments, characterised in that (a) an aqueous pigment dispersion, containing at least one organic pigment (P), selected from the group of azo, isoindolinone, isoindoline, anthanthrone, thioindigo, thiazinindigo, triarylcarbonium, quinophthalone, anthraquinone, dioxazine, phthalocyanine, quinacridone, quinacridonquinone, indanthrone, perylene, perinone, pyranthrone, diketopyrrolopyrrole, isoviolanthrone and azomethine pigments, at least one detergent (T), and water is prepared, (b) a monomer miniemulsion, stabilised by a hydrophobic organic compound with a water solubility at 20 DEG C of at most 5x10<-5> g/l, is prepared from a polymerisable monomer (M) and at least one detergent (T) in water, (c) a monomer pigment emulsion is prepared, whereby the aqueous dispersion from (a) and the monomer miniemulsion from (b) are mixed and homogenised and (d) the pigment-containing monomer from (c) is polymerised in the presence of a polymerisation initiator and/or by heat, whereupon an encapsulation of the pigment with the polymer thus formed occurs.

Solid forms comprising (+)-2-[l-(3-Ethoxy-4-methoxyphenyl)-2- methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione, compositions comprising the solid forms, methods of making the solid forms and methods of their use are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-alpha or the inhibition of PDE4.

The invention discloses an application of a rhodamine B based fluorescence sensor which can specifically detect tin ions. According to the application, benzyl 3-(3', 6'-bis(diethyl amino)-3-oxo-spiro [isoindoline-1, 9'-xanthene]-2-yl) ethyl propionate is taken as a substrate, different heavy metal ions such as MgCl2*6H2O, SnCl2*H2O, CrCl3*6H2O, AgNO3, CaCl2, NaCl, PbCl2, KCl, MnCl2*4H2O, ZnCl2, CuCl2*2H2O, LiCl*H2O, Ba(NO3)2, HgCl2, CoCl2, FeCl2*4H2O, FeCl3*6H2O, CdCl2*2.5H2O, AlCl3 and the like are added, and fluorescent response is found only when SnCl2*H2O is added, so that the fluorescence sensor which can specifically detect tin ions is developed. The sensor has the advantages of high specificity and sensitivity and the like and has important application potentials in the aspects of disease diagnosis and health evaluation.

The invention discloses a fluorescence sensor for rhodamine B as well as preparation and a detection application thereof to Fe<3+>. The rhodamine B is used as a raw material to synthesize (2-(2-(((1H-pyrrol-2-yl)methyl)amino)ethyl)-3',6'-bis(dithylamino)spiro(isoindoline-1,9'-xanthen)-3-one). The structure is used as a substrate and a solution is prepared by the substrate; different metal ions are added into the solution; after ultraviolet visible light and fluorescence tests are carried out, ultraviolet and fluorescence absorption values are obviously changed after FeCl3*6H2O is added; in a certain range, the ultraviolet and fluorescence absorption values and the concentration of the Fe<3+> are in a linear relation so as to invent the fluorescence sensor for specially detecting the Fe<3+> based on the rhodamine B. The sensor has great application potential in medical and environmental sciences.

Compounds of a certain formula (I) wherein R1, R2, R3, X, Y, r, s, t, u and v have the meanings as defined in the specification, and the salts, solvates and hydrates thereof are novel effective HDAC 6 inhibitors.

The invention discloses a rhodamine B-based fluorescent sensor, preparation and application thereof. 2-(2-aminoethyl)-3',6'-bis(diethyl-amino)spiro[isoindoline-1,9'-xanthen]-3-one(A) and 4-(1,4,7,10-tetraoxa-13-azacycl-opentadecan-13-yl)-4-oxobutanoicacid(B) are taken as precursors to synthesize a fluorescent sensor (C). After addition of different heavy metal ions like NaCl, LiCl.H2O, KCl, NiCl, CuCl, AgNO3, SnCl2.2H2O, Ba(NO3)2, MnCl2.4H2O, ZnCl12, MgCl2.6H2O, CaCl2, CdCl2.2.5H2O, CuCl2.2H2O, FeCl2.4H2O, PbCl2, CoCl2.6H2O, HgCl2, Pd(C2H3O2)2, RhCl3.H2O, IrCl3, AlCl3, FeCl3.6H2O, and CrCl3.6H2O, analysis by ultraviolet-visible spectrum and spectrofluorimetry finds that the sensor only responses to iron ions, so that the fluorescent sensor can be used for specially detecting iron ions. The sensor has advantages of high sensitivity, simple operation and good specificity, and has important potential significance in disease diagnosis.

The invention relates to a synthesis method for 5-aminolevulinic acid hydrochloride. The synthesis method comprises the steps as follows: taking 1,3-dichloroacetone as a starting material, carrying out Gabriel reaction on the 1,3-dichloroacetone and phthalimide potassium in a water phase or an organic phase to obtain a high-purity intermediate (I), 2-(3-chloro-2-oxopropyl)isoindoline-1,3-diketone; reacting the intermediate (I) with malonic acid isopropyl ester or malonic acid diethyl ester in alkali condition to prepare an intermediate (II), 2-(3-(2,2-dimethyl-4,6-dioxo-1,3-dioxane-5-yl)-2-oxopropyl)isoindoline-1,3-diketone or an intermediate (III), 2-(3-(1,3-dioxoisobenzazole-2-yl)-2-oxopropyl)malonic acid diethyl ester; and hydrolyzing, decarboxylating and post-processing to obtain the high-purity 5-aminolevulinic acid hydrochloride.

Provided are 4'-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

The invention relates to a method for preparing 3-imino isoindoline ketone compounds and particularly discloses a method for preparing the 3-imino isoindoline ketone compounds through the activation method of palladium catalysis of the C-H bond, wherein the 3-imino isoindoline ketone compounds are as shown in the formula I (refer to the Specification). The method comprises the following steps: under the existence of an inert solvent, under the catalysis of a palladium catalyst, and under the action of an oxidizing agent, the compounds II (N-alkoxy amide compounds) and the compounds III (isonitrile compounds) react to obtain the compounds I, wherein the structures of the compounds I, compounds II and compounds III are as shown in the Specification. The method is high in efficiency, excellent in selectivity, economical, environment friendly, fewer in steps, simple and convenient to operate, wide in application range of substrates, and excellent in atom economy. The invention further provides a method for further conversion of the compounds I.

There is provided a pharmaceutical composition comprising (1) (R)-5,6-dimethoxy-2-[2,2,4,6,7-pentamethyl-3-(4-methylphenyl)-2,3-dihydro-1-benzofuran-5-yl]isoindoline, (2) a lipophilic component, and (3) a surfactant, which can stably and sufficiently provide improvement in the absorbability of the drug without being affected by the amount and quality of a meal.

A liquid developer of the present invention includes a toner particle and an insulating liquid, the toner particle including a resin and a pigment, the resin including a polyester resin, the pigment including a first pigment, a second pigment, and a third pigment, the first pigment being a carbon black, 10 to 25 mass % of the first pigment being included in the toner particle, the second pigment being nigrosine, 3 to 15 mass % of the second pigment being included in the toner particle, the third pigment being at least one organic pigment selected from a group consisting of a phthalocyanine blue pigment, a phthalocyanine green pigment, a carmine-based pigment, a naphthol-based pigment, a quinacridon-based pigment, an azo-based pigment, a benzimidazolone-based pigment, and an isoindoline-based pigment, 5 to 20 mass % of the third pigment being included in the toner particle.